Filtered By:
Drug: Temodar
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 1478 results found since Jan 2013.
Reduced YAP1 and FOLR1 in gliomas predict better response to chemotherapeutics
This study also highlights the novel role of FOLR1 as a probable prognostic marker in gliomas, predicting responsiveness to temozolomide and other DNA damaging agents.PMID:37269960 | DOI:10.1016/j.cellsig.2023.110738
Source: Cellular Signalling - June 3, 2023 Category: Cytology Authors: Shruti Patrick Kirti Lathoria Vaishali Suri Ellora Sen Source Type: research
Discovery of new imidazotetrazinones with potential to overcome tumor resistance
We describe the design, organic synthesis, and characterization, including X-ray crystallography, of a series of novel analogues of the clinically used antitumor agent temozolomide, together with their in vitro biological evaluation. The work has resulted in the discovery of a new series of anticancer imidazotetrazines that offer the potential to overcome the resistance mounted by tumors against temozolomide. The rationally designed compounds that incorporate a propargyl alkylating moiety and a thiazole ring as isosteric replacement for a carboxamide, are readily synthesized (gram-scale), exhibit defined solid-state struct...
Source: European Journal of Medicinal Chemistry - June 1, 2023 Category: Chemistry Authors: Helen S Summers William Lewis Huw E L Williams Tracey D Bradshaw Christopher J Moody Malcolm F G Stevens Source Type: research
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial
CONCLUSIONS AND RELEVANCE: The findings of this nonrandomized clinical trial suggest that camrelizumab plus apatinib and temozolomide may be a potential first-line treatment option for patients with advanced acral melanoma, which warrants further validation in a randomized clinical trial.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04397770.PMID:37261804 | DOI:10.1001/jamaoncol.2023.1363
Source: Cancer Control - June 1, 2023 Category: Cancer & Oncology Authors: Lili Mao Bin Lian Caili Li Xue Bai Li Zhou Chuanliang Cui Zhihong Chi Xinan Sheng Xuan Wang Bixia Tang Xieqiao Yan Siming Li Yan Kong Jie Dai Xiaoting Wei Juan Li Rong Duan Huayan Xu Xiaowen Wu Yue Yang Fengzhuo Cheng Cheng Zhang Fangzhou Xia Zheng Pang J Source Type: research
The first evidence of biological activity for free Hypusine, an enigmatic amino acid discovered in the '70s
Amino Acids. 2023 May 31. doi: 10.1007/s00726-023-03283-4. Online ahead of print.ABSTRACTHypusine amino acid [Nε-(4-amino-2-hydroxybutyl)-lysine] was first isolated in 1971 from bovine brain extracts. Hypusine originates from a post-translational modification at the eukaryotic translation initiation factor 5A (eIF5A), a protein produced by archaebacteria and eukaryotes. The eIF5A protein is the only one described containing the hypusine residue, which is essential for its activity. Hypusine as a free amino acid is a consequence of proteolytic degradation of eIF5A. Herein, we showed, for the first time, evidence of biologi...
Source: Amino Acids - May 31, 2023 Category: Biochemistry Authors: Leticia Tamborlin Karina Danielle Pereira Dimitrius Santiago Passos Sim ões Fróes Guimarães Leonardo Reis Silveira Augusto Ducati Luchessi Source Type: research
The DRD2 antagonist haloperidol mediates autophagy-induced ferroptosis to increase temozolomide sensitivity by promoting endoplasmic reticulum stress in glioblastoma
CONCLUSIONS: Our results provide experimental evidence for repurposing HP as an effective adjunct therapy to inhibit adaptive TMZ resistance in order to enhance the efficacy of chemoradiotherapy in GBM, a strategy that may have broad prospects for clinical application.PMID:37249604 | DOI:10.1158/1078-0432.CCR-22-3971
Source: Clinical Cancer Research - May 30, 2023 Category: Cancer & Oncology Authors: Linyong Shi Hanning Chen Kunxiang Chen Chengzong Zhong Chong Song Yifeng Huang Tong Wang Lei Chen Chiyang Li Annie Huang Hong Li Yuntao Lu Source Type: research
Combination of B7H6-siRNA and temozolomide synergistically reduces stemness and migration properties of glioblastoma cancer cells
This study aimed to understand the potential role and molecular mechanism of the combination therapy of B7H6-siRNA and temozolomide in glioblastoma cancer. U87 cells were treated with B7H6-siRNA and temozolomide, separately and in combination. Cell viability, stemness, cell migration, and apoptosis were measured. The results of this work presented the synergistic effect of B7H6-siRNA and temozolomide in inhibiting the cancerous features of the U87 cell line. Down-regulating B7H6-siRNA expression inhibited the cell viability of U87 glioblastoma cancer cells and increased their sensitivity to temozolomide. In addition, a not...
Source: Experimental Cell Research - May 29, 2023 Category: Cytology Authors: Nadia Allahyarzadeh Khiabani Mohammad Amin Doustvandi Fateme Mohammadnejad Elnaz Salmani Hassan Kohal Neda Boushehri Mahdi Jafarlou Behzad Baradaran Source Type: research
